Quantitative analysis of cerebral vasculopathy in patients with Fabry disease

被引:146
作者
Crutchfield, KE
Patronas, NJ
Dambrosia, JM
Frei, KP
Banerjee, TK
Barton, NW
Schiffmann, R
机构
[1] NINDS, Dev & Metab Neurol Branch, NIH, Bethesda, MD 20892 USA
[2] NIH, Warren Grant Magnuson Clin Ctr, Dept Diagnost Radiol, Bethesda, MD 20892 USA
[3] NINDS, Biometry Branch, NIH, Bethesda, MD 20892 USA
关键词
D O I
10.1212/WNL.50.6.1746
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective: This study's purpose was to obtain a quantitative natural history of the cerebrovascular involvement in Fabry disease. Background: Fabry disease is an X-linked recessive disorder due to ol-galactosidase A deficiency. Progressive accumulation of ceramidetrihexoside within the intima and media of cerebral blood vessels causes ischemic lesions in the majority of affected patients. Determination of the natural history of the cerebral vasculopathy in Fabry disease is important to assess the effects of therapeutic intervention in this disorder. Methods: A longitudinal MRI study of 50 patients who had a total of 129 MRI scans was performed. The burden of cerebrovascular disease was determined using direct linear measurement. Results: On T2-weighted MRI scans, 32% of the patients had no lesions (mean age, 33 years), 16% had gray matter lesions only (mean age, 36 years), 26% had lesions in white matter only (mean age, 43 years), and 26% had lesions in white and gray matter (mean age, 47 years). Disease burden increased with age, but no patient younger than 26 had lesions on MRI. All patients older than 54 had cerebrovascular involvement. The distribution of MRI-detectable lesions was typical of a small-vessel disease. Only 37.5% of patients with cerebral lesions had neurologic symptoms. Conclusion: These findings provide a predictable outcome measure to assess the effect of molecular interventions on the cerebrovascular circulation in Fabry disease.
引用
收藏
页码:1746 / 1749
页数:4
相关论文
共 22 条
[1]   ENZYMATIC DEFECT IN FABRYS DISEASE - CERAMIDETRIHEXOSIDASE DEFICIENCY [J].
BRADY, RO ;
GAL, AE ;
BRADLEY, RM ;
MARTENSS.E ;
WARSHAW, AL ;
LASTER, L .
NEW ENGLAND JOURNAL OF MEDICINE, 1967, 276 (21) :1163-&
[2]   REPLACEMENT THERAPY FOR INHERITED ENZYME DEFICIENCY - USE OF PURIFIED CERAMIDETRIHEXOSIDASE IN FABRYS-DISEASE [J].
BRADY, RO ;
TALLMAN, JF ;
JOHNSON, WG ;
GAL, AE ;
LEAHY, WR ;
QUIRK, JM ;
DEKABAN, AS .
NEW ENGLAND JOURNAL OF MEDICINE, 1973, 289 (01) :9-14
[3]   ENZYME THERAPY IN FABRY DISEASE - DIFFERENTIAL INVIVO PLASMA-CLEARANCE AND METABOLIC EFFECTIVENESS OF PLASMA AND SPLENIC ALPHA-GALACTOSIDASE-A ISOZYMES .12. [J].
DESNICK, RJ ;
DEAN, KJ ;
GRABOWSKI, G ;
BISHOP, DF ;
SWEELEY, CC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1979, 76 (10) :5326-5330
[4]  
Desnick RJ, 1996, METABOLIC MOL BASES, P2741
[5]   FABRY DISEASE - IMMUNOCYTOCHEMICAL CHARACTERIZATION OF NEURONAL INVOLVEMENT [J].
DEVEBER, GA ;
SCHWARTING, GA ;
KOLODNY, EH ;
KOWALL, NW .
ANNALS OF NEUROLOGY, 1992, 31 (04) :409-415
[6]   Interscanner variation in brain MRI lesion load measurements in MS: Implications for clinical trials [J].
Filippi, M ;
vanWaesberghe, JH ;
Horsfield, MA ;
Bressi, S ;
Gasperini, C ;
Yousry, TA ;
GawneCain, ML ;
Morrissey, SP ;
Rocca, MA ;
Barkhof, F ;
Nijeholt, GJLA ;
Bastianello, S ;
Miller, DH .
NEUROLOGY, 1997, 49 (02) :371-377
[7]   LACUNES - SMALL DEEP CEREBRAL INFARCTS [J].
FISHER, CM .
NEUROLOGY, 1965, 15 (08) :774-&
[8]   THE USE OF BRAIN MAGNETIC-RESONANCE-IMAGING IN MULTIPLE-SCLEROSIS [J].
GOODKIN, DE ;
RUDICK, RA ;
ROSS, JS .
ARCHIVES OF NEUROLOGY, 1994, 51 (05) :505-516
[9]  
GREWAL RP, 1994, J NEUROL, V241, P153
[10]   ANDERSON-FABRY DISEASE - HISTOPATHOLOGICAL STUDY OF 3 CASES WITH OBSERVATIONS ON MECHANISM OF PRODUCTION OF PAIN [J].
KAHN, P .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1973, 36 (06) :1053-1062